TCRX
Tscan Therapeutics Inc

786
Mkt Cap
$64.41M
Volume
61,398.00
52W High
$6.23
52W Low
$1.02
PE Ratio
-1.04
TCRX Fundamentals
Price
$1.12
Prev Close
$1.14
Open
$1.11
50D MA
$1.94
Beta
1.10
Avg. Volume
763,452.00
EPS (Annual)
-$1.14
P/B
0.36
Rev/Employee
$14,515.46
Loading...
Loading...
News
all
press releases
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +36.00% and +55.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
More News
News Placeholder
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +73.65% and +22.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 0.00% and +58.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of +12.96% and +0.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews
Latest Ratings for TCRX DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Aug 2021Cowen & Co.Initiates Coverage OnOutperform Aug 2021Morgan StanleyInitiates Coverage...
Benzinga·1y ago
News Placeholder
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Latest Ratings for TCRX DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Aug 2021Cowen & Co.Initiates Coverage OnOutperform Aug 2021Morgan StanleyInitiates Coverage...
Benzinga·1y ago
News Placeholder
TScan Therapeutics (TCRX) Gets a Buy from Wedbush
In a report released today, David Nierengarten from Wedbush assigned a Buy rating to TScan Therapeutics (TCRX Research Report), with a price targ...
TipRanks Financial Blog·1y ago
News Placeholder
Buy Rating Affirmed for TScan Therapeutics Amidst Strong Pipeline Progress and Robust Financial Health
In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on TScan Therapeutics (TCRX Research Report), with a pri...
TipRanks Financial Blog·1y ago

Latest TCRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.